Skip to main navigation
Skip to search
Skip to main content
Ben-Gurion University Research Portal Home
Help & FAQ
Home
Profiles
Research output
Research units
Prizes
Press/Media
Student theses
Projects
Activities
Datasets
Research Labs / Equipment
Search by expertise, name or affiliation
Dapagliflozin and cardiovascular outcomes in type 2 diabetes
DECLARE–TIMI 58 Investigators
Faculty of Health Sciences
Research output
:
Contribution to journal
›
Article
›
peer-review
5176
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Dapagliflozin and cardiovascular outcomes in type 2 diabetes'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Cardiovascular Outcomes
100%
Dapagliflozin
100%
Confidence Interval
77%
Hazard Ratio
66%
Low Dose Rate
66%
Major Adverse Cardiovascular Events
55%
Heart Failure Hospitalization
55%
Cardiovascular Mortality
55%
Placebo
44%
Atherosclerotic Cardiovascular Disease (ASCVD)
33%
Type 2 Diabetic Patients
33%
Cardiovascular Hospitalizations
33%
Placebo Groups
22%
Safety Outcomes
22%
Non-inferiority
22%
Primary Safety
22%
Efficacy Outcomes
22%
Serious Adverse Events
11%
Myocardial Infarction
11%
Mortality Hazard
11%
Safety Profile
11%
Estimated Glomerular Filtration Rate
11%
End-stage Renal Disease
11%
Ischemic Stroke
11%
Myocardial Ischemia
11%
Diabetic Ketoacidosis
11%
Failure Hazard
11%
Between-group Difference
11%
Sodium-glucose Cotransporter
11%
Outcome Analysis
11%
Renal Death
11%
Body Surface Area
11%
AstraZeneca
11%
Cardiovascular Therapy
11%
Selective Inhibitor
11%
Cardiovascular Safety
11%
Genital Infection
11%
Efficacy Analysis
11%
Upper Boundary
11%
Renal Events
11%
Glucosuria
11%
Pharmacology, Toxicology and Pharmaceutical Science
Dapagliflozin
100%
Non Insulin Dependent Diabetes Mellitus
100%
Placebo
66%
Congestive Heart Failure
55%
Cardiovascular Disease
55%
Coronary Artery Atherosclerosis
33%
Combination Therapy
11%
Adverse Event
11%
Heart Infarction
11%
Brain Ischemia
11%
End Stage Renal Disease
11%
Diabetic Ketoacidosis
11%
Glucosuria
11%
Genital Tract Infection
11%
Sodium Glucose Cotransporter 2
11%